ArticleTranslational stroke research2025
High Plasma Sarcosine Levels Are Associated with Decreased Risks of Adverse Outcomes After Ischemic Stroke: A Multicenter Prospective Study.
Article in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Sarcosine has been reported to improve ischemic tolerance in animal models of brain ischemia, but population-based evidence from patients with ischemic stroke is lacking. We conducted a multicenter prospective study to investigate the associations between plasma sarcosine levels and adverse outcomes among patients with ischemic stroke. We measured plasma sarcosine levels among 3473 patients with ischemic stroke from 26 hospitals across China. The primary outcome was the composite outcome of death or major disability (modified Rankin Scale [mRS] score, 3-6) at 3 months after ischemic stroke. Secondary outcomes were major disability (mRS score, 3-5), death (mRS score, 6), and cardiovascular events. During 3 months of follow-up, 853 participants experienced the primary outcome. Compared with the lowest quartile of sarcosine, the multivariable-adjusted odds ratios or hazard ratios of the highest quartile were 0.59 (P
Indexed as
Identifiers
40715975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.